21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
23:26 , May 14, 2019 |  BC Extra  |  Clinical News

Daiichi gets ODAC split, with FDA panel backing pexidartinib for rare cancer

Missing data and lingering safety questions dogged a pair of Daiichi Sankyo oncology agents that came before ODAC on Tuesday, but a lack of available treatment options for tenosynovial giant cell tumor and a clear...
17:10 , Apr 23, 2019 |  BC Innovations  |  Distillery Therapeutics

SLC27A2 inhibition for lymphoma, lung, colorectal and cervical cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; T cell lymphoma; colorectal cancer; cervical cancer Mouse studies suggest inhibiting SLC27A2 could help treat T cell lymphoma and lung, colorectal and cervical cancers. In mouse models of T...
15:54 , Apr 17, 2019 |  BC Extra  |  Financial News

Turning Point gains after pricing upsized $166.5M IPO

Turning Point shares jumped $10.90 (61%) to $28.90 in their first day of trading Wednesday after the company raised $166.5 million in an upsized IPO priced late Tuesday. Turning Point Therapeutics Inc. (NASDAQ:TPTX) sold 9.3...
13:54 , Apr 15, 2019 |  BC Extra  |  Financial News

Chi-Med planning Hong Kong listing

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) announced its intent to list on the Hong Kong stock exchange via a global offering. The company has submitted an application seeking a listing in 3Q19; terms have yet...
18:59 , Apr 12, 2019 |  BC Week In Review  |  Company News

ODAC to discuss Daiichi Sankyo's pexidartinib, quizartinib NDAs

FDA’s Oncologic Drugs Advisory Committee will meet on May 14 to discuss two NDAs from Daiichi Sankyo, one for pexidartinib to treat symptomatic tenosynovial giant cell tumors and the other for quizartinib to treat relapsed...
23:01 , Mar 21, 2019 |  BC Extra  |  Financial News

Qiming backs Abbisko in $42M series B

Abbisko raised a $42 million series B round led by new investor Qiming Venture Partners to advance its oncology compounds into the clinic and further expand its discovery pipeline. Abbisko Therapeutics Co. Ltd. (Shanghai, China)...
00:00 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Patient sample and mouse studies suggest depleting microglia with CSF1R inhibitors could help treat chemotherapy-induced neurological dysfunction. In postmortem frontal lobe tissue samples from pediatric and young adult patients treated with methotrexate and...
19:06 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round on Oct. 19 and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational...
18:27 , Oct 19, 2018 |  BC Week In Review  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...